Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14 - PubMed (original) (raw)
Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14
Norman Wolmark et al. J Clin Oncol. 2016.
Abstract
Purpose: We determined the utility of the 21-Gene Recurrence Score (RS) in predicting late (> 5 years) distant recurrence (LDR) in stage I and II breast cancer within high and low-ESR1-expressing groups.
Patients and methods: RS was assessed in chemotherapy/tamoxifen-treated, estrogen receptor (ER) -positive, node-positive National Surgical Adjuvant Breast and Bowel Project B-28 patients and tamoxifen-treated, ER-positive, node-negative B-14 patients. The association of the RS with risk of distant recurrence (DR) 0 to 5 years and those at risk > 5 years was assessed. An ESR1 expression cut point was optimized in B-28 and tested in B-14.
Results: Median follow-up was 11.2 years for B-28 and 13.9 years for B-14. Of 1,065 B-28 patients, 36% had low (< 18), 34% intermediate (18 to 30), and 30% high (≥ 31) RS. Of 668 B-14 patients, 51% had low, 22% intermediate, and 27% high RS. Median ESR1 expression by reverse transcriptase polymerase chain reaction was: B-28, 9.7 normalized expression cycle threshold units (CT) and B-14, 10.7 CT. In B-28, RS was associated with DR 0 to 5 years (log-rank P < .001) and > 5 to 10 years (log-rank P = .02) regardless of ESR1 expression. An ESR1 expression cut point of 9.1 CT was identified in B-28. It was validated in B-14 patients for whom the RS was associated with DR in years 5 to 15: 6.8% (95% CI, 4.4% to 10.6%) versus 11.2% (95% CI, 6.2% to 19.9%) versus 16.4% (95% CI, 10.2% to 25.7%) for RS < 18, RS 18 to 30, and RS ≥ 31, respectively (log-rank P = .01).
Conclusion: For LDR, RS is strongly prognostic in patients with higher quantitative ESR1. Risk of LDR is relatively low for patients with low RS. These results suggest the value of extended tamoxifen therapy merits evaluation in patients with intermediate and high RS with higher ESR1 expression at initial diagnosis.
Trial registration: ClinicalTrials.gov NCT01420185.
© 2016 by American Society of Clinical Oncology.
Conflict of interest statement
Authors’ disclosures of potential conflicts of interest are found in the article online at www.jco.org. Author contributions are found at the end of this article.
Figures
Fig 1.
CONSORT diagram. AC, doxorubicin plus cyclophosphamide; AC→P, doxorubicin plus cyclophosphamide followed by paclitaxel; ER, estrogen receptor; GHI, Genomic Health, Inc.; IBC, invasive breast cancer; NSABP, National Surgical Adjuvant Breast and Bowel Project; qPCR, quantitative polymerase chain reaction; RT-PCR, reverse transcriptase polymerase chain reaction; RTX, radiotherapy; TAM, tamoxifen.
Fig 2.
Kaplan-Meier curves and estimates for distant recurrence risk in B-28 and B-14 by recurrence score risk groups and time period. Event counts are for those occurring within the time period shown. (A) Curves for B-28, 0 to 5 years; (B) curves for B-28, 5 to 10 years; (C) curves for B-14, 0 to 5 years; (D) curves for B-14, 5 to 15 years.
Fig 3.
Kaplan-Meier curves and estimates for distant recurrence risk in B-28 by recurrence score risk groups, ESR1 expression level, and time period. (A) Curves for ESR1 ≤ 9.1, time 0 to 5 years; (B) curves for ESR1 ≤ 9.1, time 5 to 10 years; (C) curves for ESR1 > 9.1, time 0 to 5 years; (D) curves for ESR1 > 9.1, time 5 to 10 years.
Fig 4.
Kaplan-Meier curves and estimates for distant recurrence risk over 5 to 15 years, by recurrence score risk groups, in high-_ESR1_–expressing patients in B-14.
Fig 5.
Forest plots with Kaplan-Meier estimates and 95% CIs for the risk of distant recurrence after 5 years by recurrence score risk group in high-_ESR1_–expressing patients, in (A) B-28 (from 5 to 10 years) and (B) B-14 (from 5 to 15 years), within subgroups according to clinical and pathology characteristics. Int, intermediate; Mod, moderate
Fig A1.
Scatter plots of recurrence score values by ESR1 expression level in NSABP B-28 and B-14. Reference lines for ESR1 expression are at the cut point for positivity by RT-PCR (6.5 CT) and at the cut point identified in B-28 (9.1 CT). (A) Plot for B-28; (B) Plot for B-14. ER, estrogen receptor.
Fig A2.
Cox model hazard ratios (and 95% CIs) for the continuous recurrence score as a predictor of distant recurrence risk in NSABP B-28, in patients with high ESR1 expression, for a range of cut point values. The x-axis is the percentile of the ESR1 distribution in NSABP B-28, annotated with the ESR1 cut point value. ER, estrogen receptor.
Fig A3.
Forest plot with Kaplan-Meier estimates and 95% CIs for distant recurrence risk by recurrence score risk group, by ESR1 expression level and time period, in NSABP B-28 patients. ER, estrogen receptor.
Fig A4.
Kaplan-Meier curves and estimates for distant recurrence risk in NSABP B-14 by recurrence score risk groups, ESR1 expression level, and time period. (A) Curves for ESR1 ≤ 9.1, time 0-5 years; (B) Curves for ESR1 ≤ 9.1, time 5-15 years; (C) Curves for ESR1 > 9.1, time 0-5 years; (D) Curves for ESR1 > 9.1, time 5-15 years.
Fig A5.
Forest plot with Kaplan-Meier estimates and 95% CIs for distant recurrence risk by recurrence score risk group, in high _ESR1_-expressing patients in NSABP B-14, by time period 0-5, 5-10, or 5-15 years.
Fig A6.
Distant recurrence risk estimates over years 5-15, with 95% CIs, in NSABP B-14 high-_ESR1_-expressing patients, as a function of the recurrence score. The estimates are based on the quadratic model.
Similar articles
- Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.
Mamounas EP, Tang G, Fisher B, Paik S, Shak S, Costantino JP, Watson D, Geyer CE Jr, Wickerham DL, Wolmark N. Mamounas EP, et al. J Clin Oncol. 2010 Apr 1;28(10):1677-83. doi: 10.1200/JCO.2009.23.7610. Epub 2010 Jan 11. J Clin Oncol. 2010. PMID: 20065188 Free PMC article. - 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.
Mamounas EP, Tang G, Paik S, Baehner FL, Liu Q, Jeong JH, Kim SR, Butler SM, Jamshidian F, Cherbavaz DB, Sing AP, Shak S, Julian TB, Lembersky BC, Lawrence Wickerham D, Costantino JP, Wolmark N. Mamounas EP, et al. Breast Cancer Res Treat. 2018 Feb;168(1):69-77. doi: 10.1007/s10549-017-4550-8. Epub 2017 Nov 11. Breast Cancer Res Treat. 2018. PMID: 29128898 Free PMC article. Clinical Trial. - 21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy.
Mamounas EP, Liu Q, Paik S, Baehner FL, Tang G, Jeong JH, Kim SR, Butler SM, Jamshidian F, Cherbavaz DB, Sing AP, Shak S, Julian TB, Lembersky BC, Wickerham DL, Costantino JP, Wolmark N. Mamounas EP, et al. J Natl Cancer Inst. 2017 Jan 25;109(4):djw259. doi: 10.1093/jnci/djw259. Print 2017 Jan. J Natl Cancer Inst. 2017. PMID: 28122895 Free PMC article. Clinical Trial. - The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O, Seghers S, Sergoynne L, Van Gaver H, Papadimitriou K, Wouters K, Trinh XB, Huizing MT, Tjalma W. Najim O, et al. Biochim Biophys Acta Rev Cancer. 2019 Dec;1872(2):188315. doi: 10.1016/j.bbcan.2019.188315. Epub 2019 Oct 21. Biochim Biophys Acta Rev Cancer. 2019. PMID: 31647985 Review. - Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M. Jahanzeb M. Clin Ther. 2007 Aug;29(8):1535-47. doi: 10.1016/j.clinthera.2007.08.013. Clin Ther. 2007. PMID: 17919537 Review.
Cited by
- Systemic Metabolic and Volumetric Assessment via Whole-Body [18F]FDG-PET/CT: Pancreas Size Predicts Cachexia in Head and Neck Squamous Cell Carcinoma.
Yu J, Spielvogel C, Haberl D, Jiang Z, Özer Ö, Pusitz S, Geist B, Beyerlein M, Tibu I, Yildiz E, Kandathil SA, Buschhorn T, Schnöll J, Kumpf K, Chen YT, Wu T, Zhang Z, Grünert S, Hacker M, Vraka C. Yu J, et al. Cancers (Basel). 2024 Sep 30;16(19):3352. doi: 10.3390/cancers16193352. Cancers (Basel). 2024. PMID: 39409971 Free PMC article. - Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial.
Mamounas EP, Bandos H, Rastogi P, Zhang Y, Treuner K, Lucas PC, Geyer CE Jr, Fehrenbacher L, Chia SK, Brufsky AM, Walshe JM, Soori GS, Dakhil S, Paik S, Swain SM, Sgroi DC, Schnabel CA, Wolmark N. Mamounas EP, et al. Clin Cancer Res. 2024 May 1;30(9):1984-1991. doi: 10.1158/1078-0432.CCR-23-1977. Clin Cancer Res. 2024. PMID: 38376912 Free PMC article. Clinical Trial. - Proposing a novel molecular subtyping scheme for predicting distant recurrence-free survival in breast cancer post-neoadjuvant chemotherapy with close correlation to metabolism and senescence.
Huang J, Zhang JL, Ang L, Li MC, Zhao M, Wang Y, Wu Q. Huang J, et al. Front Endocrinol (Lausanne). 2023 Oct 12;14:1265520. doi: 10.3389/fendo.2023.1265520. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37900131 Free PMC article. Review. - Biomarkers predictive of a response to extended endocrine therapy in breast cancer: a systematic review and meta-analysis.
Woolpert KM, Ahern TP, Lash TL, O'Malley DL, Stokes AM, Cronin-Fenton DP. Woolpert KM, et al. Breast Cancer Res Treat. 2024 Feb;203(3):407-417. doi: 10.1007/s10549-023-07149-x. Epub 2023 Oct 25. Breast Cancer Res Treat. 2024. PMID: 37878151 Free PMC article. Review. - Long-term prognostic value of the GenesWell BCT score in Asian women with hormone receptor-positive/HER2-negative early breast cancer.
Fujiki Y, Kashiwaba M, Sato M, Kawano J, Teraoka M, Kanemitsu S, Rai Y, Taira T, Sagara Y, Ohi Y, Jo U, Lee YW, Lee SB, Gong G, Shin YK, Kwon MJ, Sagara Y. Fujiki Y, et al. Breast Cancer. 2024 Jan;31(1):31-41. doi: 10.1007/s12282-023-01509-7. Epub 2023 Oct 9. Breast Cancer. 2024. PMID: 37812303 Free PMC article.
References
MeSH terms
Substances
Grants and funding
- U10 CA180868/CA/NCI NIH HHS/United States
- UG1 CA189867/CA/NCI NIH HHS/United States
- U10 CA012027/CA/NCI NIH HHS/United States
- U24 CA114732/CA/NCI NIH HHS/United States
- U10 CA069651/CA/NCI NIH HHS/United States
- U24 CA075362/CA/NCI NIH HHS/United States
- U24 CA196067/CA/NCI NIH HHS/United States
- U10 CA069974/CA/NCI NIH HHS/United States
- U10 CA180822/CA/NCI NIH HHS/United States
- U10 CA037377/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous